NCT00336973View on ClinicalTrials.gov

A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent

PHASE4CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

February 29, 2008

Conditions
Psoriasis
Interventions
DRUG

efalizumab

Subcutaneous repeating dose

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY